---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-019112"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2025-10-23T23:59:59+00:00"
generated_at: "2026-05-17T02:29:54.231011+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics appoints Kameel Farag as interim CFO

## Summary
- Kameel Farag appointed interim CFO effective October 22, 2025; succeeds Torsten Hombeck.
- Compensation: $18,000/month cash + $12,000 in RSUs for Oct-Dec 2025; increases in Jan-Feb 2026.
- Consultant also entitled to 1.0% of capital raise proceeds up to $200,000 cap (0.5% after term).
- Consulting agreement runs through February 16, 2026, with possible month-to-month extensions.

## SEC filing metadata
- accession: 0001493152-25-019112
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2025-10-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000149315225019112/0001493152-25-019112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000149315225019112/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-019112
- JSON: https://secwatch.observer/filing/0001493152-25-019112.json
- Plain text: https://secwatch.observer/filing/0001493152-25-019112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.